Anyone can ‘predict’ whether your asset works. Only BioCorteX tells you for whom, and more importantly, why.
Right drug. First time. For all.
We show you for whom assets work - and why.
BioCorteX is a top-tier VC backed tech bio. Every pharmaceutical interacts with the bacteria that live in and on us, and those bacteria differ from one population to the next. That difference is why an asset can succeed in one region and fail in another.
We run in‑silico bridge trials that map this interaction before the clinic - so science, regulatory and commercial teams can move an asset from one population to another with confidence.
Where AI predicts whether an asset works, BioCorteX proves for whom, and why: transparent, auditable, mechanism‑first.
The platform behind every bridge trial.
Mirroring evolutionary biology, NeoCorteX was built out of necessity to address arguably the highest‑stakes intersection of scientific complexity and regulatory scrutiny - health.
Biology is the variable. We make it predictable.
Working in partnership with
